Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility

The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...
July 06, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Board of Directors to Promote Buyback Program of up to $1 Million

TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of...
June 29, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome

TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
June 23, 2022 09:30 ET | Source: SciSparc Ltd

SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
May 19, 2022 08:30 ET | Source: Vyant Bio, Inc.

Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference

Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
March 28, 2022 16:30 ET | Source: Vyant Bio, Inc.

Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021

CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
March 24, 2022 08:00 ET | Source: VistaGen Therapeutics, Inc.

VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to...
February 14, 2022 16:15 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update

- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...
February 10, 2022 16:20 ET | Source: VistaGen Therapeutics, Inc.

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD)...
February 08, 2022 10:00 ET | Source: Precedence Research

Central Nervous System Therapeutic Market Size to Hit US$ 209.2 Bn by 2030

Ottawa, Feb. 08, 2022 (GLOBE NEWSWIRE) -- The global central nervous system therapeutics market size was valued at US$ 113.6 billion in 2020. The rising prevalence of various central nervous system...